From Nasdaq: 2025-04-21 02:34:00

Eli Lilly stock is up after successful late-stage trial results for a daily obesity pill, showing effectiveness in lowering blood sugar and reducing weight. The pill’s safety profile is comparable to Ozempic. The convenience of a daily pill could give Eli Lilly an edge over Novo Nordisk.

Eli Lilly stock looks expensive compared to the S&P 500 based on price-to-sales and price-to-earnings ratios. Revenues have grown significantly over recent years, with strong profit margins. The company’s balance sheet is strong with a low debt-to-equity ratio.

During recent downturns, LLY stock has been more resilient than the S&P 500. The stock fully recovered after the Covid pandemic and inflation shock. Overall, Eli Lilly has shown strong growth, profitability, financial stability, and downturn resilience, making it a strong buy with potential upside.



Read more at Nasdaq: Should You Buy Eli Lilly Stock At $820?